IFRX · InflaRx N.V.

Summary

InflaRx reports favorable reactive metabolite profile for izicopan in human liver microsomes, suggesting lower bioactivation risk versus avacopan.

Key takeaways

• Izicopan showed minimal reactive metabolite formation in GSH trapping assay, indicating low bioactivation potential.
• Avacopan exhibited higher levels of thiol adducts, consistent with more extensive oxidative bioactivation.
• Differences in conjugate peak areas exceeded 100-fold at early time points and remained ~10-fold at later points.
• In vitro findings do not directly predict clinical outcomes but support izicopan's differentiated profile.
• Izicopan is an investigational oral C5aR1 inhibitor with potential for improved efficacy and safety.